Group B streptococcus (GBS) is a leading cause of morbidity and mortality in newborns worldwide. From 2000 to 2008, national guidelines in Germany recommended intrapartum antibiotic prophylaxis for pregnant women displaying risk factors (eg, perinatal anogenital GBS colonization, rupture of the membranes ≥18 hours before birth) for the vertical transmission of GBS to their children. In 2008, these guidelines were revised to advocate universal, culture-based screening for GBS colonization among all pregnant women between 35 and 37 weeks of gestation. For the period 2009–2010, our prospective active surveillance study assessed the incidence of invasive GBS infections in infants 0–90 days of age in Germany. We did this by means of a capture–recapture analysis of 2 separate, independent systems (pediatric reporting versus laboratory reporting). We compared our results with those from a previous study by employing an equivalent design (2001–2003). We detected a 32% reduction in GBS incidence, from 0.47 per 1000 live births (n = 679) in 2001–2003 to 0.34 per 1000 live births (n = 450) in 2009–2010. This decline primarily is tied to a reduced number of GBS cases in children under 1 week of age. In 2009–2010, the ratio of early-onset disease to late-onset disease reversed from 1.52 (206:136), as determined in 2001–2003, to 0.75 (92:122). This study is the first to assess changes in the incidence of invasive GBS in Germany after the implementation of the guidelines for intrapartum prophylaxis for pregnant women colonized with GBS.
From the *Department of Anaesthesiology and Operative Intensive Care Medicine, Charité-Universitätsmedizin Berlin, Germany
†Robert Koch-Institute Germany, Berlin, Germany
‡Department of Pediatrics, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
§Department of Pediatrics, University Medical Center Freiburg, Freiburg, Germany
¶Epidemiology Department, Helmholtz Centre for Infection Research, Braunschweig, Germany
‖Institute for Infectious Disease Epidemiology, TWINCORE, Hannover, Germany
**Translational Infrastructure Epidemiology, German Centre for Infection Research (DZIF), Germany.
Accepted for publication May 10, 2018.
The authors have no funding or conflicts of interest to disclose.
Address for correspondence: Gérard Krause, MD, Epidemiology Department, Helmholtz Centre for Infection Research, Inhoffenstraße 7, 38124 Braunschweig, Germany. E-mail: Gerard.Krause@helmholtz-hzi.de.